OMED.XX News
Archived Headlines
- US IPO Recap: Seven deals price, five set terms as busy July continues 07/22/13
- OncoMed Pharmaceuticals prices upsized IPO at $17, above the range 07/17/13
- OncoMed Pharma increases shares offered, proposed IPO deal size now $72 million 07/17/13
- 7 US IPOs planned for the week of Jul 15 07/15/13
- US IPO Recap: July calendar heats up as 13 companies set terms 07/15/13
See more
Cancer biotech TRACON Pharmaceuticals sets terms for $47 million IPO
TRACON Pharmaceuticals, which is developing antibodies to treat cancer, AMD and fibrotic diseases, announced terms for its IPO on Tuesday. The San Diego, CA-based company plans to raise $47 million by offering 3.6 million shares at a price range of $12 to $14....read more
Cancer biotech Kolltan Pharmaceuticals files for an $86 million IPO
Kolltan Pharmaceuticals, an early-stage biotech developing antibodies to treat solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Kolltan is in Phase 1 trials for its antibody-based drugs that...read more
Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO
Alder BioPharmaceuticals, a biotech developing antibodies to treat migraines and arthritis, filed on Wednesday with the SEC to raise up to $115 million in an initial public offering. The Bothell, WA-based company, which was founded in 2002 and booked $19 million...read more
Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues
Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The...read more